Prometheus Biosciences Inc is a biotechnology & medical research business based in the US. Prometheus Biosciences Inc shares (RXDX) are listed on the NASDAQ and all prices are listed in US Dollars. Prometheus Biosciences Inc employs 97 staff and has a trailing 12-month revenue of around $4 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $0.00 - $0.00 |
|---|---|
| 50-day moving average | $189.46 |
| 200-day moving average | $112.93 |
| Wall St. target price | $190.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-3.54 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
| Revenue TTM | $4 million |
|---|---|
| Gross profit TTM | $-106,039,000 |
| Return on assets TTM | -20.06% |
| Return on equity TTM | -33.3% |
| Profit margin | 0% |
| Book value | $14.62 |
| Market Capitalization | $9.6 billion |
TTM: trailing 12 months
We're not expecting Prometheus Biosciences Inc to pay a dividend over the next 12 months.
You may also wish to consider:
Prometheus Biosciences Inc's shares were split on a 1:100 basis on 31 October 2013 . So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Prometheus Biosciences Inc shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Prometheus Biosciences Inc shares which in turn could have impacted Prometheus Biosciences Inc's share price.
Over the last 12 months, Prometheus Biosciences Inc's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Prometheus Biosciences Inc's is -0.4857. This would suggest that Prometheus Biosciences Inc's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Prometheus Biosciences Inc has bucked the trend.
To put Prometheus Biosciences Inc's beta into context you can compare it against those of similar companies.
Prometheus Biosciences, Inc. , a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.